BOSTON, Jan. 08, 2026 — Leads & Copy — Tango Therapeutics, Inc. (NASDAQ: TNGX) has announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today, January 8, 2026. Dr. Weber, the company’s founding CEO, will transition to Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She will be succeeded by Dr. Malte Peters, a current board member, who is appointed President and Chief Executive Officer, effective immediately.
Dr. Peters, a leader with clinical development and leadership experience, has served on the Tango Board of Directors since 2018. He will now drive the next phase of company growth.
In her new role as Executive Chair, Dr. Weber will remain involved with the senior management team, supporting the company’s strategic priorities and working with Dr. Peters to ensure a seamless transition and continued clinical execution throughout 2026. Alexis Borisy, the current Board Chair, will transition to Lead Independent Director.
Dr. Weber expressed her pride in the team’s accomplishments over the past eight years, emphasizing the advancement of their mission to improve outcomes for people with cancer. She noted that with vopimetostat progressing into its first registrational trial and combination studies, now is the right time for Dr. Peters’ leadership to propel Tango into its next growth phase.
Dr. Weber also highlighted her confidence in Dr. Peters’ late-stage clinical development expertise and commitment to patients, anticipating his expertise will drive success as they move vopimetostat into pivotal studies and commercialization.
Mr. Borisy thanked Dr. Weber for her visionary leadership and dedication, especially in advancing vopimetostat. He also expressed confidence in Tango’s future under Dr. Peters’ leadership.
Dr. Peters conveyed his honor in joining Tango’s executive team and acknowledged Dr. Weber and the team’s accomplishments. He looks forward to working with Dr. Weber, the Board, and the executive team to build on the company’s foundation and pursue their shared vision.
Dr. Peters previously served as Chief Research and Development Officer at MorphoSys AG, following his tenure as Chief Development Officer and board member since March 2017, where he oversaw a large development organization and the global regulatory approval of Monjuvi in combination with lenalidomide in diffuse large B cell lymphoma. Earlier in his career, he was Global Head of Clinical Development for the Biopharmaceuticals Business Unit at Sandoz International. He also held key leadership positions at Novartis as Clinical Head and Site Head for Basel and East Hanover in Oncology Translational Medicine. He earned his medical degree from the Freie Universität Berlin, Germany.
Tango Therapeutics also renewed its guidance on anticipated clinical milestones in 2026, including:
- Combination trial with vopimetostat + daraxonrasib, and vopimetostat + zoldonrasib (Revolution Medicines), phase 1/2 initial safety and efficacy data.
- Vopimetostat monotherapy Phase 1/2 clinical data lung cancer update.
- Vopimetostat monotherapy 2L pancreatic cancer pivotal study start.
- TNG456 monotherapy phase 1/2 trial initial safety and efficacy data.
Elizabeth Hickin
IR@tangotx.com
media@tangotx.com
Source: Tango Therapeutics, Inc.
